EVANSTON, Ill., Oct. 3 /PRNewswire-FirstCall/ -- Northfield Laboratories
Inc. (Nasdaq: NFLD) today announced that IVS Associates, the independent
inspector of elections at Northfield's September 13 annual meeting of
shareholders, has submitted its certification of the final voting results from
the meeting. The certified results confirm that, as previously reported, each
of Northfield's seven director nominees has been elected by a significant
margin. According to the IVS report, each of Northfield's seven director
nominees received more than 6.3 million votes. Each of the two director
nominees proposed by C. Robert Coates received 4.4 million votes. The
proposal to ratify the appointment of Northfield's independent auditors has
also been approved overwhelmingly by shareholders.
Steven A. Gould, M.D., Northfield's Chairman and Chief Executive Officer,
commented, "We are pleased this process is completed. We value the opinions
and input of all our shareholders. I am grateful that Mr. Bierbaum and Dr.
Ness are joining our Board and look forward to adding their expertise to that
of the entire Board as we move forward toward the commercialization of
PolyHeme."
"As I stated at the meeting, we are evaluating many alternatives to
enhance and maximize shareholder value over the long term. As we pursue our
goals, I am committed to keeping our shareholders informed about our progress
on a regular basis. I am pleased to announce that we will be hosting our
first quarterly conference call on October 16th. Details will be available on
our website http://www.northfield.com and a press release will be distributed
shortly," Dr. Gould said.
Statements in this release that are not strictly historical are "forward-
looking" statements that are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, which may cause the company's
actual results in the future to differ materially from expected results. These
risks include, among others: competition from other blood substitute products;
the company's ability to obtain regulatory approval to market PolyHeme
commercially; the company's and/or its representative's ability to
successfully market and sell PolyHeme; the company's ability to manufacture
PolyHeme in sufficient quantities; the company's ability to obtain an adequate
supply of raw materials; the company's ability to maintain intellectual
property protection for its proprietary product and to defend its existing
intellectual property rights from challenges by third parties; the
availability of capital to finance planned growth; and the extent to which the
hospitals and physicians using PolyHeme are able to obtain third-party
reimbursement, as described in the company's filings with the Securities and
Exchange Commission.
Visit the Northfield website at: http://www.northfieldlabs.com .
SOURCE Northfield Laboratories Inc.
 back to top
Related links:
http://www.northfieldlabs.com
CONTACT:
Steven A. Gould, M.D., Chief Executive
Officer, +1-847-864-3500, or Investors, Sophia Twaddell,
+1-847-864-3500, both of Northfield Laboratories; or Media, Cindy
Martin of FRB Weber Shandwick, +1-312-640-6741
|
